Ubrogepant
- Generic Name
- Ubrogepant
- Brand Names
- Ubrelvy
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26F3N5O3
- CAS Number
- 1374248-77-7
- Unique Ingredient Identifier
- AD0O8X2QJR
- Background
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor antagonists, belonging to a class of med...
- Indication
Ubrogepant is indicated for the acute treatment of migraine with or without aura in adults.
- Associated Conditions
- Migraine With Aura, Migraine Without Aura
- Associated Therapies
- -
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
- Conditions
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1254
- Registration Number
- NCT02873221
- Locations
- 🇺🇸
Kentucky Pediatric Research Inc, Bardstown, Kentucky, United States
🇺🇸Quest Research Institute, Farmington Hills, Michigan, United States
🇺🇸Aventura Neurological Associates, PA, Aventura, Florida, United States
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
- Conditions
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1686
- Registration Number
- NCT02867709
- Locations
- 🇺🇸
Cedars Sinai Pain Center, Los Angeles, California, United States
🇺🇸Rapid Medical Research, Inc., Cleveland, Ohio, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
- Conditions
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1672
- Registration Number
- NCT02828020
- Locations
- 🇺🇸
Prime Care Clinical Research, Laguna Hills, California, United States
🇺🇸Medical Center for Clinical Research, San Diego, California, United States
🇺🇸Clinical Research Advantage, Inc./Diagnostic Center of Medicine - Durango, Las Vegas, Nevada, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.